Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 455-462

  Zamboni, William C ^a   Houghton, Peter J ^a,b   Thompson, Joyce ^a   Cheshire, Pamela J ^a   Hanna, Suzan K ^a   Richmond, Lois B ^a   Lou, Xiaolong ^a   Stewart, Clinton F ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLESTERASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL COMPARTMENTALIZATION; COMPARTMENT MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISPOSITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; MOUSE; NEUROBLASTOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; PRODRUGS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031889264     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85: 271-291, 1993.
2. Creemers, G. J., Lund, B., and Verweij, J. New drugs: topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73-96, 1994.
3. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21: 1159-1169, 1991.
4. Sasaki, Y., Hakusui, Y., Mizuno, S., Morita, M., Miya, T., and Eguchi, K. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite, SN-38. Jpn. J. Cancer Res., 86: 101-110, 1995.
5. Tsuji, T., Kaneda, N., Kado, K., Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. Pharmacobio-Dyn., 14: 341-349, 1991.
6. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836-842, 1994.
7. Drewinko, B., Freireich, E. J., and Gottlieb, J. A. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res., 34: 747-750, 1974.
8. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G. J. Irinotecan (CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2: 1943-1949, 1996.
9. Wall, M. E., and Wani, M. C. Chemistry and antitumor activity of camptothecins. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 93-102. New York: Oxford University Press, 1991.
10. Rosen, E. M., Cassady, J. R., Frantz, C. N., Kretschmar, C. S., Levey, C. S., and Sallan, S. E. Neuroblastoma. The joint center for radiation therapy/Dana Farber Cancer Institute/Children's Hospital Experience. J. Clin. Oncol., 2: 799-803, 1984.
11. Vassal, G., Morizet, J., Bissery, M. C., Boland, I., Ardouin, P., Mathieu-Boue, A., and Gouyette, A. Activity of the camptothecin analog CPT-11 (irinotecan) against medulloblastoma xenografts. Proc. Annu. Meet. Am. Assoc. Cancer Res., 35: A2183, 1994.
12. Komuro, H., Li, P., Tsuchida, Y., Yokomori, K., Nakajima, K., Aoyama, T., Kaneko, M., and Kaneda, N. Effects of CPT-11 (a unique DNA topoisomerase inhibitor) on a highly malignant xeno-transplanted neuroblastoma. Med. Pediatr. Oncol., 23: 487-492, 1994.
13. Stewart, C. F., Zamboni, W. C., Crom, W. R., and Houghton, P. J. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother. Pharmacol., 40: 259-265, 1997.
14. Chabot, G. G., Gouyette, A., and Bissery, M. C. Tumor influence on pharmacokinetics of the camptothecin analogue irinotecan (CPT-11) and active metabolite SN-38 in mice. Proc. Am. Assoc. Cancer Res., 35: 432, 1994.
15. Veronesi, B., and Ehrich, M. Using neuroblastoma cell lines to examine organophosphate neurotoxicity. In Vitro Toxicol., 6: 57-65, 1993.
16. Ehrich, M., and Veronesi, B. Esterase comparison in neuroblastoma cells of human and rodent origin. Clin. Exp. Pharmacol. Physiol., 22: 328-386, 1995.
17. Ehrich, M., Correll, L., Carlson, K., Wilcke, J., and Veronesi, B. Examination of culture conditions on esterase activities in human and mouse neuroblastoma cells. In Vitro Toxicol., 8: 199-207, 1995.
18. Veronesi, B., and Ehrich, M. Differential cytotoxic sensitivity in mouse and human cell lines exposed to organophosphate insecticides. Toxicol. Appl. Pharmacol., 120: 240-246, 1993.
19. Houghton, P. J., Houghton, J. A., Myers, L., Cheshire, P. J., Howbert, J. J., and Grindey, G. B. Evaluation of N-(5-indanylsulfonyl)-N′-(4-chlorophenyl) urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol., 25: 84-89, 1989.
20. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X., Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res., 3: 423-432, 1997.
21. Rivory, L. P., and Robert, J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantification of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J. Chromatogr. B Biomed. Appl., 661: 133-141, 1994.
22. Yeh, K. C., and Kwan, K. C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J. Pharmacokinet. Biopharm., 6: 79-98, 1978.
23. Gibaldi, M., and Perrier, D. Pharmacokinetics. New York: Marcel Dekker, 1982.
24. Neter, J., Wasserman, W., and Kutner, M. H. Applied Linear Statistical Models. New York: Irwin, 1990.
25. Kato, R., and Takahashi, A. Decreased hydroxylation of steroid hormones by liver microsomes from rats bearing walker carcinoma 256. Cancer Res., 30: 2346-2352, 1970.
26. Sladek, N. E., Domeyer, B. E., Merriman, R. L., and Brophy, G. T. Differential effects of Walker 256 carcinosarcoma cells growing subcutaneously, intramuscularly, or intraperitoneally on hepatic microsomal mixed function oxygenase activity. Drug Metab. Dispos., 6: 412-417, 1978.
27. Rosso, R., Donelli, M. G., Franchi, G., and Garattini, S. Impairment of drug metabolism in tumor-bearing animals. Eur. J. Cancer, 7: 565-577, 1971.
28. Prueksaritanont, T., Gorham, L. M., Hochman, J. H., Tran, L. O., and Vyas, K. P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in CACO-2 cells. Drug Metab. Dispos., 24: 634-642, 1996.
29. Lund-Pero, M., Jeppson, B., Arneklo-Nobin, B., Sjogren, H-O., Holmgren, K., and Pero, R. W. Non-specific steroidal esterase activity and distribution in human and other mammalian tissues. Clin. Chim. Acta, 224: 9-20, 1994.
30. Hosokawa, M., Endo, T., Fujisawa, M., Hara, S., Iwata, N., Sato, Y., and Satoh, T. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab. Dispos., 23: 1022-1027, 1995.
31. Chen, S. F., Rothenberg, M. L., Clark, G., Degen, D., Wajima, M., Barton, D., and Von Hoff, D. D. Human tumor carboxylesterase activity correlates with CPT-11 cytotoxicity in vitro. Proc. Am. Assoc. Cancer Res., 35: A2174, 1994.
32. Kanzawa, F., Kondoh, H., Kwon, S. J., and Saijo, N. Role of carboxylesterase on metabolism of camptothecin analog (CPT-11) in non-small cell lung cancer cell line PC-7 cells. Proc. Am. Assoc. Cancer Res., 33: 427, 1992.
33. Ogasawara, H., Nishio, K., Kanzawa, F., Lee, Y-S., Funayama, Y., Ohira, T., Kuraishi, Y., Isogai, Y., and Saijo, N. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn. J. Cancer Res., 86: 124-129, 1995.
34. van Leeuwen, P. A. M., Drukker, J., van Der Kleyn, N. M., van Den Boogaard, A. E. J. M., and Soeters, P. B. Morphological effects of high dose neomycin sulfate on the small and large intestine. Acta Morphol. Neerl.-Scand., 24: 223-234, 1986.